ライフサイエンスコーパス: arteriovenous

1 oarterial, venovenous, venovenoarterial, and arteriovenous.

2 HMB we also measured muscle proteolysis (by arteriovenous (A-V) dilution).

3 d an AVF (n=295) or AVG (n=105) placed or no arteriovenous access (CVC group, n=71).

4 point, serious adverse events involving the arteriovenous access circuit within 30 days, was assesse

5 ficiaries of Medicare undergoing their first arteriovenous access placement in 2009 were identified b

6 Results First arteriovenous access was performed in 1479 beneficiaries

7 I), and 20 of 24 eyes (83.3%) had peripheral arteriovenous anastomoses (Goldberg II) in addition.

8 Intrapulmonary arteriovenous anastomoses (IPAVA) have been known to exi

9 aphy suggest that anatomical intra-pulmonary arteriovenous anastomoses (IPAVAs) are present at rest a

10 Blood flow through intrapulmonary arteriovenous anastomoses (IPAVAs) has been demonstrated

11 ia-induced blood flow through intrapulmonary arteriovenous anastomoses (QIPAVA ) are currently unknow

12 increased blood flow through intrapulmonary arteriovenous anastomoses (QIPAVA ) in healthy humans at

13 les suggests that anatomical intra-pulmonary arteriovenous anastomoses are recruited during exercise,

14 d the safety and efficacy of a central iliac arteriovenous anastomosis to alter the mechanical arteri

15 Arteriovenous anastomosis was associated with significan

16 icate that aplexone differentially regulates arteriovenous angiogenesis by targeting the HMG-CoA redu

17 79; P=0.017); among the 198 patients with an arteriovenous (AV) access at randomization, the risk was

18 more likely to undergo surgery to create an arteriovenous (AV) fistula or place an AV graft.

19 ysis vascular access recommendations promote arteriovenous (AV) fistulas first; however, it may not b

20 Arteriovenous (AV) fistulas for hemodialysis can lead to

21 nal drug release in the context of synthetic arteriovenous (AV) grafts used for chronic hemodialysis.

22 Synthetic arteriovenous (AV) hemodialysis grafts are plagued by hy

23 Arteriovenous (AV) malformation (AVM) is a devastating c

24 A side-to-side arteriovenous (AV) shunt was created between the distal

25 perfusion techniques to detect and quantify arteriovenous (AV) shunting and tumor hypoxia in patient

26 BM include marked vascular heterogeneity and arteriovenous (AV) shunting, which results in tumor hypo

27 (AVMs) are tortuous vessels characterized by arteriovenous (AV) shunts, which displace capillaries an

28 perinsulinemic-euglycemic clamp with femoral arteriovenous balance and glucose tracer was applied aft

29 Using the arteriovenous balance technique, we studied the effect o

30 esence of unstable bradycardia or high-grade arteriovenous block in the absence of myocardial dysfunc

31 esence of unstable bradycardia or high-grade arteriovenous block without significant alteration in ca

32 orders characterized by localized lesions of arteriovenous, capillary, or lymphatic origin.

33 enous nickings do not necessarily involve an arteriovenous compression.

34 ing was examined by measuring differences in arteriovenous concentrations across the forearm muscle.

35 ight lean subjects were studied by measuring arteriovenous concentrations of metabolites and ATBF on

36 ment and stabilization of normally transient arteriovenous connections.

37 vicular arteries and veins was measured with arteriovenous contrast ratio (AVCR) and contrast-to-nois

38 in a 1:1 ratio to undergo implantation of an arteriovenous coupler device plus current pharmaceutical

39 ssure reduced by 26.9 (SD 23.9) mm Hg in the arteriovenous coupler group (p<0.0001) and by 3.7 (21.2)

40 e reduced by 13.5 (18.8) mm Hg (p<0.0001) in arteriovenous coupler recipients and by 0.5 (15.8) mm Hg

41 (43%) of 195 patients screened were assigned arteriovenous coupler therapy (n=44) or normal care (n=3

42 Implantation of the arteriovenous coupler was associated with late ipsilater

43 tially regulated by the HMGCR pathway via an arteriovenous-dependent requirement for protein prenylat

44 clamp, TNF-alpha perfusion increased glucose arteriovenous differences (0.91 +/- 0.17 vs. 0.74 +/- 0.

45 chromatography-tandem mass spectrometry and arteriovenous differences adjusted for blood flow.

46 omprehensive biochemical characterization of arteriovenous differences has not yet been reported.

47 own regulators of vascular morphogenesis and arteriovenous differentiation during development.

48 be malformed and fragile, and they can lose arteriovenous differentiation.

49 ox18/Vegfd and Sox7/Vegfd exhibit defects in arteriovenous differentiation.

50 l players in the complex regulation of human arteriovenous EC identity.

51 icial placenta strategies have been based on arteriovenous ECLS using the umbilical vessels with mode

52 involvement of PTPN14 in angiogenesis and/or arteriovenous fate, acting via EphrinB2 and ACVRL1/activ

53 Arteriovenous fistula (AVF) access improves survival in

54 The persistence of a patent arteriovenous fistula (AVF) after transplantation may co

55 mes have been established with the use of an arteriovenous fistula (AVF) at first hemodialysis.

56 CorMatrix wrapped around the outflow vein of arteriovenous fistula (AVF) at the time of creation coul

57 Creation of a hemodialysis arteriovenous fistula (AVF) causes aberrant vascular mec

58 ing minimal threshold diameters for surgical arteriovenous fistula (AVF) creation but fails to improv

59 rmed routinely for vascular mapping prior to arteriovenous fistula (AVF) creation for hemodialysis bu

60 Arteriovenous fistula (AVF) is the preferred type of vas

61 Arteriovenous fistula (AVF) is the preferred vascular ac

62 Arteriovenous fistula (AVF) maturation failure is the pr

63 of the competing risk of death, high rate of arteriovenous fistula (AVF) maturation failure, and poor

64 Low rates of arteriovenous fistula (AVF) maturation prevent optimal f

65 enefit when initiating hemodialysis (HD) via arteriovenous fistula (AVF) or arteriovenous graft (AVG)

66 and subsequently undergo placement of a new arteriovenous fistula (AVF) or arteriovenous graft (AVG)

67 is one of the most important determinants of arteriovenous fistula (AVF) success.

68 senting at least one cerebral or spinal pial arteriovenous fistula (AVF), and to describe their clini

69 g incident dialysis patients: (1) placing an arteriovenous fistula (AVF1st) as the initial access fol

70 ge, cerebrovascular malformations, and dural arteriovenous fistula affecting the basal ganglia, their

71 approaches in mouse and human SMC, and human arteriovenous fistula and cardiac allograft vasculopathy

72 is upregulated in human intimal hyperplastic arteriovenous fistula and cardiac allograft vasculopathy

73 Despite efforts to increase arteriovenous fistula and graft use, 80% of patients in

74 central venous catheter and transition to an arteriovenous fistula and graft, our observational cohor

75 ux hemodialysis may benefit patients with an arteriovenous fistula and patients with diabetes and tha

76 rebral haemorrhage due to intracranial dural arteriovenous fistula and presented our personal experie

77 Clinical practice guidelines recommend an arteriovenous fistula as the preferred vascular access f

78 le venous limb outward remodeling, preserved arteriovenous fistula blood flow, and prolonged primary

79 ing primary radiocephalic or brachiocephalic arteriovenous fistula creation were randomly assigned (1

80 fects suggests that these drugs might reduce arteriovenous fistula failure.

81 Dural arteriovenous fistula is a very rare cause of myelitis t

82 Native arteriovenous fistula is one of the important routes for

83 effect on mortality of programmed VA (PVA), (arteriovenous fistula or PTFE graft) and nonprogrammed V

84 nd angiography revealed a pseudoaneurysm and arteriovenous fistula originating from the right interna

85 o evidence that statins improve experimental arteriovenous fistula patency and maturation, indicating

86 The primary endpoint was arteriovenous fistula patency at 3 months.

87 us fistula blood flow, and prolonged primary arteriovenous fistula patency through day 42 (P<0.05 ver

88 with local anaesthesia improved medium-term arteriovenous fistula patency.

89 n therapy in patients on dialysis undergoing arteriovenous fistula placement is warranted.

90 evelopment include carotid body ablation and arteriovenous fistula placement.

91 alendar year with elective open AAA repairs, arteriovenous fistula repairs, or carotid endarderectomy

92 t pulsatile tinnitus caused by a small dural arteriovenous fistula revealed in computed tomography an

93 es after ligation injury and in failed human arteriovenous fistula samples after occlusion by dediffe

94 predictive than duplex US of the outcome of arteriovenous fistula surgery.

95 We concomitantly analyzed the in vivo arteriovenous fistula thrombogenic and inflammatory macr

96 the lower risk of mortality associated with arteriovenous fistula use in hemodialysis patients is du

97 Arteriovenous fistula use increased only minimally, from

98 Arteriovenous fistula utilization at initial hemodialysi

99 jacent to vessels, and PSAs with concomitant arteriovenous fistula were referred to MC (n=145, 34%).

100 32.7% of 74,194 patients transitioned to an arteriovenous fistula, 10.8% transitioned to an arteriov

101 ssociations between type of vascular access (arteriovenous fistula, arteriovenous graft, and central

102 e prognosis when compared with those with an arteriovenous fistula, but the role of vascular access (

103 error, interobserver variability, bleeding, arteriovenous fistula, graft loss, and even death.

104 left heart failure, high cardiac output from arteriovenous fistula, hypoxic lung diseases, and metabo

105 ed with patients undergoing dialysis with an arteriovenous fistula, those doing so via a catheter had

106 er demonstrating right T7 to T8 spinal dural arteriovenous fistula.

107 n objective was the salvage of a functioning arteriovenous fistula.

108 nce angiography of his abdominal vessels and arteriovenous fistula.

109 lysis for the treatment of thrombosed native arteriovenous fistula.

110 edure for the treatment of thrombosed native arteriovenous fistula.

111 implemented an incentive if patients use an arteriovenous fistula.

112 as angiosarcomas might be correlated with an arteriovenous fistula.

113 nts, 20% of sarcomas arose at the site of an arteriovenous fistula.

114 Arteriovenous fistulae (AVF) are the most common access

115 Arteriovenous fistulae are the optimum form of vascular

116 Local Anaesthesia versus Regional Block for Arteriovenous Fistulae, NCT01706354.

117 y improved 3 month primary patency rates for arteriovenous fistulae.

118 About half of arteriovenous fistulas (AVFs) require one or more interv

119 ntima formation causes the failure of 60% of arteriovenous fistulas (AVFs) within 2 years.

120 hesia improves short-term blood flow through arteriovenous fistulas (AVFs).

121 are causes of tinnitus include cranial dural arteriovenous fistulas (DAVFs), which are usually small

122 x (CVR) in patients with lateral sinus dural arteriovenous fistulas (DAVFs).

123 complete cure in most cases of spinal dural arteriovenous fistulas (SDAVF), there has been an increa

124 cised if accessible, while hemorrhagic dural arteriovenous fistulas and distal/mycotic aneurysms are

125 Arteriovenous fistulas and pseudoaneurysms concerning in

126 vascular lesions such as pseudoaneurysms and arteriovenous fistulas associated with the internal pude

127 ion, both symptomatic and asymptomatic dural arteriovenous fistulas deserve clinical attention, struc

128 enotic lesions in dysfunctional hemodialysis arteriovenous fistulas during the 6 months after the pro

129 The relative rate of thrombosis of native arteriovenous fistulas for the highest quartile of intra

130 Arteriovenous fistulas placed surgically for dialysis va

131 nts needing hemodialysis are advised to have arteriovenous fistulas rather than catheters because of

132 llow-up clinically and radiologically, dural arteriovenous fistulas should be kept in mind in the eti

133 restenotic lesions in native upper-extremity arteriovenous fistulas were eligible for participation.

134 was reviewed, and 25 patients with 28 dural arteriovenous fistulas were identified.

135 -dependent when waitlisted, individuals with arteriovenous fistulas were significantly less likely th

136 In arteriovenous malformations and dural arteriovenous fistulas, ASL is very sensitive to detect

137 ith the low-flux group for the subgroup with arteriovenous fistulas, which constituted 82% of the stu

138 racranial haemorrhage in patients with dural arteriovenous fistulas.

139 xperience in endovascular treatment of dural arteriovenous fistulas.

140 t al. in an associated Article) and share an arteriovenous fluid-mixing reservoir.

141 ears) with CKD undergoing predialysis AVF or arteriovenous graft (AVG) creation from 2004 to 2009, an

142 ysis (HD) via arteriovenous fistula (AVF) or arteriovenous graft (AVG) vs hemodialysis catheter (HC),

143 ment of a new arteriovenous fistula (AVF) or arteriovenous graft (AVG).

144 Innovations in arteriovenous graft materials range from small modificat

145 velopment in a porcine model of hemodialysis arteriovenous graft stenosis.

146 of intradialytic hypotension with prosthetic arteriovenous graft thrombosis after multivariable adjus

147 eriovenous fistula, 10.8% transitioned to an arteriovenous graft, 32.1% stayed on a CVC, and 24.5% di

148 e of vascular access (arteriovenous fistula, arteriovenous graft, and central venous catheter) and ri

149 Utilization rates of AVF, arteriovenous graft, and intravascular hemodialysis cath

150 However, polytetrafluoroethylene arteriovenous grafts are prone to thrombosis, infection,

151 Arteriovenous grafts were created in wild-type or FSP-1-

152 Synthetic arteriovenous grafts, an important option for hemodialys

153 graft patency of newly created hemodialysis arteriovenous grafts, but the individual contributions o

154 othelial growth dynamics or a lack of proper arteriovenous identity but instead seem to feature exube

155 R2F2 regulated 3 distinct aspects related to arteriovenous identity.

156 ation is associated with acquisition of dual arteriovenous identity; increased Eph-B activity improve

157 The arteriovenous loop (AVL) has been an extensively studied

158 Congenital arteriovenous malformation (AVM) in the pelvic area is u

159 Arteriovenous malformation (AVM) is a fast-flow, congeni

160 A uterine arteriovenous malformation (AVM) is a rare cause of uter

161 Arteriovenous malformation (AVM) is an abnormal connecti

162 Extracranial arteriovenous malformation (AVM) is most commonly caused

163 better outcome prediction for patients with arteriovenous malformation (AVM)-related intracerebral h

164 Capillary malformation-arteriovenous malformation (CM-AVM) is a blood and lymph

165 Capillary malformation-arteriovenous malformation (CM-AVM) is an autosomal domi

166 ant vascular disorder capillary malformation-arteriovenous malformation (CM-AVM).

167 RASA1 mutations cause capillary malformation-arteriovenous malformation (CM-AVM); whether it also fun

168 n the international, multicentre Genetics of Arteriovenous Malformation (GEN-AVM) consortium.

169 We report on a case of pancreatic arteriovenous malformation (PAVM) that obliterated short

170 Renal arteriovenous malformation (RAVM) is a rare disease.

171 Ang-2 therefore may contribute to arteriovenous malformation formation and subsequent blee

172 lformation: the most common and severe brain arteriovenous malformation in neonates.

173 reatment options in patients with unruptured arteriovenous malformation in the future.

174 Two recent studies in unruptured brain arteriovenous malformation management - ARUBA (a multice

175 resent a promising therapeutic treatment for arteriovenous malformation patients.

176 clusion Smoking is associated with pulmonary arteriovenous malformation persistence after embolizatio

177 A1-related disorders (capillary malformation-arteriovenous malformation syndrome).

178 ing to a diagnosis of capillary malformation/arteriovenous malformation type 1.

179 ients (>/=18 years) with an unruptured brain arteriovenous malformation were enrolled into this trial

180 stroke in patients with an unruptured brain arteriovenous malformation who are allocated to either m

181 n 21 subjects with epilepsy, brain tumor, or arteriovenous malformation who had undergone IAP and MEG

182 tive tool for the treatment of brain tumors, arteriovenous malformation, and functional conditions.

183 cally associated with capillary malformation-arteriovenous malformation, but sporadic reports of lymp

184 ny age, and had Gamma Knife radiosurgery for arteriovenous malformation, trigeminal neuralgia, or ben

185 18 years) diagnosed with an unruptured brain arteriovenous malformation, who had never undergone inte

186 The recently published arteriovenous malformation-related intracerebral haemorr

187 stroke in patients with an unruptured brain arteriovenous malformation.

188 nt feeding artery, which was consistent with arteriovenous malformation.

189 mab to treat the macular oedema in a case of arteriovenous malformation.

190 ted] as assessed by development of pulmonary arteriovenous malformation.

191 4905 patients), meningiomas (1490 [30.4%]), arteriovenous malformations (1089 [22.2%]), trigeminal n

192 A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) aims to compare the

193 In A Randomized trial of Unruptured Brain Arteriovenous malformations (ARUBA), randomisation was h

194 As brain arteriovenous malformations (AVM) and intracranial aneur

195 Liver arteriovenous malformations (AVM) in hereditary hemorrha

196 n may result in angiogenesis, and ultimately arteriovenous malformations (AVM), through transforming

197 ventricular aneurysms (n = 3/24), pulmonary arteriovenous malformations (AVMs) (n = 5/24), and proxi

198 Brain arteriovenous malformations (AVMs) are abnormal tangles

199 Cerebral arteriovenous malformations (AVMs) are common vascular m

200 Arteriovenous malformations (AVMs) are fragile direct co

201 Congenital pelvic arteriovenous malformations (AVMs) are high-flow vascula

202 Extracranial arteriovenous malformations (AVMs) are rare but dangerou

203 Arteriovenous malformations (AVMs) are tortuous vessels

204 Pelvic arteriovenous malformations (AVMs) are uncommon lesions

205 Spinal arteriovenous malformations (AVMs) can lead to developme

206 Arteriovenous malformations (AVMs) have an inherent capa

207 Arteriovenous malformations (AVMs) in organs, such as th

208 enetic bleeding disorder leading to systemic arteriovenous malformations (AVMs), is caused by loss-of

209 Because mutations in ALK1 cause arteriovenous malformations (AVMs), our findings suggest

210 onnections between arteries and veins called arteriovenous malformations (AVMs), which can hemorrhage

211 after stereotactic radiosurgery for cerebral arteriovenous malformations (AVMs).

212 characterized by excessive angiogenesis with arteriovenous malformations (AVMs).

213 t connections between arteries and veins, or arteriovenous malformations (AVMs).

214 es to life-threatening visceral and cerebral arteriovenous malformations (AVMs).

215 l hypervascularization and the appearance of arteriovenous malformations (AVMs).

216 acterized by local telangiectases and larger arteriovenous malformations (AVMs); but how ENG function

217 Brain arteriovenous malformations (bAVMs) are an important cau

218 nterventional treatment for unruptured brain arteriovenous malformations (bAVMs) is uncertain because

219 The pathogenesis of sporadic brain arteriovenous malformations (BAVMs) remains unknown, but

220 d includes arrhythmias, edema, and pulmonary arteriovenous malformations (PAVM) among others.

221 Within the past decade, pulmonary arteriovenous malformations (PAVMs) have evolved from ra

222 ss is a recognized complication of pulmonary arteriovenous malformations (PAVMs) that allow systemic

223 standard of care for treatment of pulmonary arteriovenous malformations (PAVMs).

224 Hemorrhagic arteriovenous malformations and cavernous malformations

225 Mice mutant for Notch1 and Notch3 develop arteriovenous malformations and display hallmarks of the

226 In arteriovenous malformations and dural arteriovenous fist

227 and unexposed children and young adults with arteriovenous malformations and in those exposed to feru

228 cular malformations (VMs) including visceral arteriovenous malformations and mucosal telangiectasia.

229 especially in the venous drainage areas, and arteriovenous malformations as determined by increased c

230 Congenital heart diseases with arteriovenous malformations carry a high risk of mortali

231 Tissue samples from patients with arteriovenous malformations displayed strong endothelial

232 or stroke in patients with unruptured brain arteriovenous malformations followed up for 33 months.

233 Finally, we demonstrate that KRAS-dependent arteriovenous malformations in zebrafish are refractory

234 The presence of arteriovenous malformations is often described when endo

235 f preventive eradication of unruptured brain arteriovenous malformations remains uncertain.

236 areful angiographic assessment of individual arteriovenous malformations should be performed before e

237 adults, matched for age and sex, with brain arteriovenous malformations who received at least one do

238 icentre randomized trial of unruptured brain arteriovenous malformations) will be of major importance

239 estigate the proper management of unruptured arteriovenous malformations, and the key factors in endo

240 n in the endothelium is sufficient for brain arteriovenous malformations, even in the setting of unin

241 This resulted in defective angiogenesis and arteriovenous malformations, leading to embryonic lethal

242 as how active KRAS signaling contributes to arteriovenous malformations, remains unknown.

243 can trigger cardiovascular diseases, such as arteriovenous malformations.

244 ular assist devices (LVADs) and is caused by arteriovenous malformations.

245 well as the presence of multiple and massive arteriovenous malformations.

246 G12D or G12V) are sufficient to induce brain arteriovenous malformations.

247 on congenital heart disease and intracranial arteriovenous malformations.

248 Final histology showed that 2 patients had arteriovenous malformations: one had a benign hemangioma

249 By arteriovenous measurements and histologic studies, local

250 ngiopoietins was measured by unique, dynamic arteriovenous measurements over the reperfused kidney.

251 Arteriovenous nickings (AVNs) in the retina are the caus

252 Arteriovenous nickings do not necessarily involve an art

253 n renal blood flow, GFR, O2 consumption, and arteriovenous O2 shunting.

254 segment close to a retinal arteriole without arteriovenous overlap were imaged by adaptive optics ima

255 de tension difference (P(v - a)Co2) over the arteriovenous oxygen content difference (C(a - v)o2).

256 as the products of F and O2A, and F and the arteriovenous oxygen content difference (O2A-V), respect

257 and combined with oxygen uptake to calculate arteriovenous oxygen content difference.

258 ts had blunted exercise-induced increases in arteriovenous oxygen content difference.

259 tterns in oxygen uptake, cardiac output, and arteriovenous oxygen content difference.

260 additional assessment of cardiac output and arteriovenous oxygen content difference.

261 thy sedentary controls, the increase in peak arteriovenous oxygen difference did not.

262 ed from linearity between heart-rate and the arteriovenous oxygen difference, present in data from ex

263 alization increased peak arterial oxygen and arteriovenous oxygen difference, whereas exercise traini

264 P1 cytoplasmic domain is required for normal arteriovenous patterning, because arteries and veins cro

265 r retina following incremental reductions in arteriovenous perfusion pressure across the retinal circ

266 E) and venules (CRVE), and summarized as the arteriovenous ratio (AVR).

267 At the systemic level, arteriovenous release of the proinflammatory cytokine in

268 etric changes in neocapillary morphogenesis, arteriovenous remodeling, and microvessel regression.

269 arterial input function was measured with an arteriovenous shunt and a beta-microprobe system.

270 ed the feasibility of IF measurement with an arteriovenous shunt and a coincidence counter in mice an

271 ive pulmonary disease underwent percutaneous arteriovenous shunt creation.

272 Fifteen patients underwent percutaneous arteriovenous shunt creation.

273 put and oxygen delivery , the creation of an arteriovenous shunt in the setting of severe chronic obs

274 Percutaneous creation of an arteriovenous shunt may increase oxygen delivery and, he

275 rsiro hybrid drug-eluting stent in a porcine arteriovenous shunt model.

276 able vascular scaffold in an ex vivo porcine arteriovenous shunt model.

277 Ir-CPI prevented clotting in catheter and arteriovenous shunt rabbit models.

278 oregulatory defences in humans are sweating, arteriovenous shunt vasoconstriction, and shivering.

279 THODS AND An ex vivo porcine carotid jugular arteriovenous shunt was established and connected to SYL

280 al IF can be measured in mice with a femoral arteriovenous shunt.

281 to an unanesthetized mouse via an implanted arteriovenous shunt.

282 xperimental models of catheter occlusion and arteriovenous shunt.

283 ntrast-enhanced MR Imaging for evaluation of arteriovenous shunting and tumor hypoxia in glioblastoma

284 (EphB4 and Jagged-1), and showed evidence of arteriovenous shunting.

285 20) were obesity (31%), liver disease (23%), arteriovenous shunts (23%), lung disease (16%), and myel

286 l-grade tubing and catheters, assembled into arteriovenous shunts and implanted in pigs, remain paten

287 rn is not suggestive for neoangiogenesis, as arteriovenous shunts from malignant tissues are responsi

288 ollagen-coated vascular grafts inserted into arteriovenous shunts in baboons, and reduced fibrin and

289 tion, and most frequently caused by obesity, arteriovenous shunts, and liver disease.

290 bnormalities (retinal-choroidal anastomoses, arteriovenous shunts, increased permeability, dilation,

291 enous-venous shunts, and 33 eyes (34.7%) had arteriovenous shunts.

292 vascular dragging, venous-venous shunts, and arteriovenous shunts.

293 al floor of the dorsal aorta concurrent with arteriovenous specification and intersegmental vessel (I

294 suggest that not all of the effects of Hh on arteriovenous specification are mediated by VEGF.

295 included hypervascularization and defects in arteriovenous specification, as well as the presence of

296 terplay between Hh and VEGF signaling during arteriovenous specification.

297 development often occurs after placement of arteriovenous synthetic grafts used for hemodialysis.

298 r, the development of hyperplasia within the arteriovenous synthetic grafts was unchanged by treatmen

299 nges include venous-venous shunting, delayed arteriovenous transit, and delayed or absent choroidal p

300 testinal fatty acid binding protein (I-FABP) arteriovenous (V-A) concentrations differences were sign